FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4284880737> ?p ?o ?g. }

• W4284880737 endingPage "218744" @default.
• W4284880737 startingPage "thoraxjnl" @default.
• W4284880737 abstract "COVID-19 severity is correlated with granulocyte macrophage colony-stimulating factor (GM-CSF) and C reactive protein (CRP) levels. In the phase three LIVE-AIR trial, lenzilumab an anti-GM-CSF monoclonal antibody, improved the likelihood of survival without ventilation (SWOV) in COVID-19, with the greatest effect in participants having baseline CRP below a median of 79 mg/L. Herein, the utility of baseline CRP to guide lenzilumab treatment was assessed.A subanalysis of the randomised, blinded, controlled, LIVE-AIR trial in which lenzilumab or placebo was administered on day 0 and participants were followed through Day 28.Hospitalised COVID-19 participants (N=520) with SpO2 ≤94% on room air or requiring supplemental oxygen but not invasive mechanical ventilation.Lenzilumab (1800 mg; three divided doses, q8h, within 24 hours) or placebo infusion alongside corticosteroid and remdesivir treatments.The primary endpoint was the time-to-event analysis difference in SWOV through day 28 between lenzilumab and placebo treatments, stratified by baseline CRP.SWOV was achieved in 152 (90%; 95% CI 85 to 94) lenzilumab and 144 (79%; 72 to 84) placebo-treated participants with baseline CRP <150 mg/L (HR: 2.54; 95% CI 1.46 to 4.41; p=0.0009) but not with CRP ≥150 mg/L (HR: 1.04; 95% CI 0.51 to 2.14; p=0.9058). A statistically significant interaction between CRP and lenzilumab treatment was observed (p=0.044). Grade ≥3 adverse events with lenzilumab were comparable to placebo in both CRP strata. No treatment-emergent serious adverse events were attributed to lenzilumab.Hospitalised hypoxemic patients with COVID-19 with baseline CRP <150 mg/L derived the greatest clinical benefit from treatment with lenzilumab.NCT04351152; ClinicalTrials.gov." @default.
• W4284880737 created "2022-07-09" @default.
• W4284880737 creator A5011873953 @default.
• W4284880737 creator A5031780276 @default.
• W4284880737 creator A5047521482 @default.
• W4284880737 creator A5048480083 @default.
• W4284880737 creator A5050046173 @default.
• W4284880737 creator A5063187039 @default.
• W4284880737 creator A5065771201 @default.
• W4284880737 creator A5072429482 @default.
• W4284880737 creator A5075575064 @default.
• W4284880737 creator A5077722019 @default.
• W4284880737 creator A5082479644 @default.
• W4284880737 creator A5089073906 @default.
• W4284880737 date "2022-07-06" @default.
• W4284880737 modified "2023-09-27" @default.
• W4284880737 title "C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial" @default.
• W4284880737 cites W2002776738 @default.
• W4284880737 cites W2163296212 @default.
• W4284880737 cites W2183362862 @default.
• W4284880737 cites W3011230498 @default.
• W4284880737 cites W3013843138 @default.
• W4284880737 cites W3027630905 @default.
• W4284880737 cites W3028583791 @default.
• W4284880737 cites W3045374676 @default.
• W4284880737 cites W3046629770 @default.
• W4284880737 cites W3081275185 @default.
• W4284880737 cites W3081723269 @default.
• W4284880737 cites W3082201689 @default.
• W4284880737 cites W3085518140 @default.
• W4284880737 cites W3087425309 @default.
• W4284880737 cites W3094585742 @default.
• W4284880737 cites W3108005071 @default.
• W4284880737 cites W3108943464 @default.
• W4284880737 cites W3118487076 @default.
• W4284880737 cites W3120017613 @default.
• W4284880737 cites W3130126061 @default.
• W4284880737 cites W3134718368 @default.
• W4284880737 cites W3165791173 @default.
• W4284880737 cites W3210756248 @default.
• W4284880737 cites W3215330689 @default.
• W4284880737 cites W4206449744 @default.
• W4284880737 doi "https://doi.org/10.1136/thoraxjnl-2022-218744" @default.
• W4284880737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35793833" @default.
• W4284880737 hasPublicationYear "2022" @default.
• W4284880737 type Work @default.
• W4284880737 citedByCount "3" @default.
• W4284880737 countsByYear W42848807372022 @default.
• W4284880737 countsByYear W42848807372023 @default.
• W4284880737 crossrefType "journal-article" @default.
• W4284880737 hasAuthorship W4284880737A5011873953 @default.
• W4284880737 hasAuthorship W4284880737A5031780276 @default.
• W4284880737 hasAuthorship W4284880737A5047521482 @default.
• W4284880737 hasAuthorship W4284880737A5048480083 @default.
• W4284880737 hasAuthorship W4284880737A5050046173 @default.
• W4284880737 hasAuthorship W4284880737A5063187039 @default.
• W4284880737 hasAuthorship W4284880737A5065771201 @default.
• W4284880737 hasAuthorship W4284880737A5072429482 @default.
• W4284880737 hasAuthorship W4284880737A5075575064 @default.
• W4284880737 hasAuthorship W4284880737A5077722019 @default.
• W4284880737 hasAuthorship W4284880737A5082479644 @default.
• W4284880737 hasAuthorship W4284880737A5089073906 @default.
• W4284880737 hasBestOaLocation W42848807371 @default.
• W4284880737 hasConcept C126322002 @default.
• W4284880737 hasConcept C142724271 @default.
• W4284880737 hasConcept C168563851 @default.
• W4284880737 hasConcept C185592680 @default.
• W4284880737 hasConcept C197934379 @default.
• W4284880737 hasConcept C203092338 @default.
• W4284880737 hasConcept C204787440 @default.
• W4284880737 hasConcept C27081682 @default.
• W4284880737 hasConcept C2776914184 @default.
• W4284880737 hasConcept C2777080012 @default.
• W4284880737 hasConcept C2779134260 @default.
• W4284880737 hasConcept C2781195455 @default.
• W4284880737 hasConcept C2781197716 @default.
• W4284880737 hasConcept C3008058167 @default.
• W4284880737 hasConcept C524204448 @default.
• W4284880737 hasConcept C55493867 @default.
• W4284880737 hasConcept C71924100 @default.
• W4284880737 hasConcept C90924648 @default.
• W4284880737 hasConceptScore W4284880737C126322002 @default.
• W4284880737 hasConceptScore W4284880737C142724271 @default.
• W4284880737 hasConceptScore W4284880737C168563851 @default.
• W4284880737 hasConceptScore W4284880737C185592680 @default.
• W4284880737 hasConceptScore W4284880737C197934379 @default.
• W4284880737 hasConceptScore W4284880737C203092338 @default.
• W4284880737 hasConceptScore W4284880737C204787440 @default.
• W4284880737 hasConceptScore W4284880737C27081682 @default.
• W4284880737 hasConceptScore W4284880737C2776914184 @default.
• W4284880737 hasConceptScore W4284880737C2777080012 @default.
• W4284880737 hasConceptScore W4284880737C2779134260 @default.
• W4284880737 hasConceptScore W4284880737C2781195455 @default.
• W4284880737 hasConceptScore W4284880737C2781197716 @default.
• W4284880737 hasConceptScore W4284880737C3008058167 @default.
• W4284880737 hasConceptScore W4284880737C524204448 @default.
• W4284880737 hasConceptScore W4284880737C55493867 @default.
• W4284880737 hasConceptScore W4284880737C71924100 @default.

• next